Vendor review
SwissChems Review
SwissChems was a well-regarded, long-running supplier through roughly 2020-2022, but by 2026 its status is genuinely mixed: an unresolved December 2024 FDA warning letter over GLP-1-class marketing, and credible mid-2026 reports of intermittent site access and unfulfilled orders, sit alongside other reviews that still show a healthy Trustpilot score. We could not directly confirm current operating status via site fetch. Given this uncertainty, we'd steer researchers toward vendors with clearer, more consistent 2026 operating signals until SwissChems' status stabilizes.
We may earn a commission when readers buy through links on this page, at no extra cost to you. Commissions never affect a vendor's score — every vendor is graded on the same public rubric built from published lab documentation, live catalog pricing, and community sentiment. How we score →
5.0
Overall score
Weighted average of six factors — see the breakdown →
SwissChems was a well-regarded, long-running supplier through roughly 2020-2022, but by 2026 its status is genuinely mixed: an unresolved December 2024 FDA warning letter over GLP-1-class marketing, and credible mid-2026 reports of intermittent site access and unfulfilled orders, sit alongside other reviews that still show a healthy Trustpilot score. We could not directly confirm current operating status via site fetch. Given this uncertainty, we'd steer researchers toward vendors with clearer, more consistent 2026 operating signals until SwissChems' status stabilizes.
SwissChems has operated since 2018 and was, for years, one of the more established names in this category — a broad catalog, publicly accessible third-party HPLC COAs, and a healthy historical Trustpilot score. It's frequently cited as a fallback recommendation after Peptide Sciences' 2026 shutdown.
By 2026, though, its status carries real caution flags we're not softening: an unresolved December 2024 FDA warning letter (MARCS-CMS 695663) cites its Semaglutide and Retatrutide product pages for marketing unapproved new drugs for human use, and multiple 2026 sources report intermittent site access, unfulfilled orders, and unresponsive support over multi-week stretches — even as other reviews from the same period still list it as active. We could not independently confirm current fulfillment via direct site fetch, which is itself part of why we've marked this vendor 'caution' rather than 'operating.' Verify current status directly before ordering.
What we like
- Long operating history (since 2018) and broad catalog relative to many competitors
- Publishes third-party HPLC-tested COAs, and some 2026 reviews still cite a healthy Trustpilot score (~4.2/5)
- Free shipping over $100 and multiple payment rails historically supported
- Frequently referenced as a Peptide Sciences alternative after that vendor's shutdown
Could be better
- Operating status is genuinely unclear as of mid-2026: multiple 2026 sources report intermittent site access, unfulfilled orders, missing order confirmations, and unresponsive support over multi-week stretches, while other reviews from the same period still list it as active — we could not independently confirm current fulfillment via direct site fetch (blocked by bot protection)
- Unresolved FDA Warning Letter (Dec 2024) specifically over Semaglutide and Retatrutide being marketed for human metabolic use rather than research use only
- Named testing lab is not consistently disclosed, weakening independent verification
- Community trust score reported as low as 3.6/10 by one 2026 reviewer, a steep decline from its 2020-2022 reputation
COA documentation
SwissChems markets independent third-party HPLC testing with COAs publicly accessible, but review sites note COA transparency "could improve" and don't identify the named lab consistently. Separately, the FDA issued Warning Letter MARCS-CMS 695663 (Dec 10, 2024) citing SwissChems' Semaglutide and Retatrutide product pages and social posts as marketing unapproved new drugs for human use; no published FDA close-out had been located as of mid-2026.
- Published
- Yes
- Third-party lab
- Yes
- Lab
- Described only as a "USA-based, HPLC-licensed laboratory"; specific lab name not consistently disclosed in public sources
Sample pricing
| Peptide | Size | Price |
|---|---|---|
| BPC-157 & TB-500 Blend | vial | $132.95 |
| GHK-Cu | varies | $68.95 |
| TB-500 | 60 capsules (0.5mg/capsule) | $254.95 |
Sources
- 1 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/swisschems-695663-12102024
- 2 https://ironpeakpeptides.com/swiss-chems-review-2026-research-peptide-alternative/
- 3 https://ironpeakpeptides.com/swiss-chems-review-alternative-2026/
- 4 https://www.peppal.app/suppliers/swisschems
- 5 https://peptidepick.com/swisschems-review/
- 6 https://swisschems.is/how-to-pay/
- 7 https://simplycodes.com/store/swisschems.is
- 8 https://muscleandbrawn.com/sarms/swiss-chems-review/
SwissChems FAQ
Is SwissChems legitimate?+
Based on our desk research, SwissChems publishes COA documentation. SwissChems was a well-regarded, long-running supplier through roughly 2020-2022, but by 2026 its status is genuinely mixed: an unresolved December 2024 FDA warning letter over GLP-1-class marketing, and credible mid-2026 reports of intermittent site access and unfulfilled orders, sit alongside other reviews that still show a healthy Trustpilot score. We could not directly confirm current operating status via site fetch. Given this uncertainty, we'd steer researchers toward vendors with clearer, more consistent 2026 operating signals until SwissChems' status stabilizes.
Does SwissChems publish third-party COAs?+
SwissChems markets independent third-party HPLC testing with COAs publicly accessible, but review sites note COA transparency "could improve" and don't identify the named lab consistently. Separately, the FDA issued Warning Letter MARCS-CMS 695663 (Dec 10, 2024) citing SwissChems' Semaglutide and Retatrutide product pages and social posts as marketing unapproved new drugs for human use; no published FDA close-out had been located as of mid-2026.
What is SwissChems best for?+
Buyers should treat SwissChems as a legacy option to verify carefully rather than a default pick, given the unresolved FDA warning letter and mid-2026 reports of order/support disruption